key: cord-0975339-g6wm18nv
authors: Huang, L.; Yao, Z.; Zhang, J.
title: Two cases of pityriasis rosea after the injection of coronavirus disease 2019 vaccine
date: 2021-09-15
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17648
sha: e9f3fdea6f65252799f7fef6031b9c5c6f4f8ab0
doc_id: 975339
cord_uid: g6wm18nv

The incidence of cutaneous manifestation in coronavirus disease 2019 (COVID-19) patients was around 20%. Among the reported cutaneous reactions after the inoculation of COVID-19 vaccination till now, the most common reactions were delayed large local reactions, local injection site reactions, urticaria, and morbilliform eruptions. Pityriasis rosea (PR) was found to be one of the rare cutaneous symptoms caused by the COVID-19 vaccination2 . Here we report 2 cases of PR after COVID-19 vaccination.

To the editor, The incidence of cutaneous manifestation in coronavirus disease 2019 (COVID-19) patients was around 20%. 1 Among the reported cutaneous reactions after the inoculation of COVID-19 vaccination till now, the most common reactions were delayed large local reactions, local injection site reactions, urticaria and morbilliform eruptions. 2 Pityriasis rosea (PR) was found to be one of the rare cutaneous symptoms caused by the COVID-19 vaccination. 2 Here, we report 2 cases of PR after the COVID-19 vaccination.

The first case was one 19-year-old man who came to the department of dermatology for 1-month history of pruritus papulosquamous lesion. His lesion appeared 2 days after the first dose injection of COVID-19 vaccine. This inactivated vaccine was produced by the Beijing Institute of Biological Products Company. His colleagues who had injected the same batch of vaccine had no similar symptoms till now. On physical examination, he had several oval pink-to-brown-coloured thin scaly plaques on the trunk and proximal extremities ( Fig. 1a-c) . Blood routine was normal. Besides, he completed 3 times of PCR test for COVID-19, and the latest test occurred the day before the visit. All negative results of the nucleic test indicated no infection of COVID-19. He was diagnosed with PR according to the classical clinical feature. After 1-week treatment of valaciclovir 300mg bid orally and mometasone furoate to inhibit itch when needed, the patient's manifestation had obvious improvement. He did not get the second dose of vaccination due to the eruption of PR after the first dose inoculation.

The second case was a 51-year-old man. He got the vaccination from the same company as the first patient as mentioned above. He developed itchy fusiform patches in the trunk 7 days after the second dose injection of COVID-19 vaccine and came to our department 3 days after the onset of the cutaneous symptom. He claimed slight similar lesions several days after the first dose inoculation without detailed picture. He reported no preceding disorder, no systemic discomfort, no cutaneous contacts or no new drug exposures. Physical examination indicated annular and oval lesion covering by thin scales across the neck, trunk, bilateral groins and proximal extremities, in a 'Christmas tree' pattern (Fig. 1d,e) . During the process, the patient had no fever, cough or any other symptoms. Based on the diagnosis of PR, we treated him with ganciclovir 250 mg bid orally and got the improvement.

PR is a self-limited papulosquamous disorder associated with virus infection. Previous study reported the onset of PR several days or several weeks after the injection of Pfizer/ BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines in white people mostly. 3 It is still controversial to define this phenomenon as PR or PR-like eruption. 4 The described cases here are the first report of PR after the COVID-19 vaccination produced by the Beijing Institute of Biological Products Company in China. Due to the small size of samples and limitation of follow-up after both doses in the vaccination population, it is still hard to calculate the incidence or define the median time of PR onset. Besides, the disparities of reactions between different races are also important issues. This eruption of PR may be caused by the similar component of allergen between the inactivated vaccine and COVID-19 mediated by T cells. 5 It will be helpful for the dermatologist to be familiar with COVID-19 vaccine-related cutaneous manifestations.

Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registrybased study of 414 cases

Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine

Pityriasis rosea and pityriasis rosea-like eruptions: how to distinguish them?

Adverse reactions to vaccines practice parameter 2012 update

The patients in this manuscript have given written informed consent to publication of their case details.

The authors state no conflict of interest.

This work was supported by grants from National Nature Science Foundation of China (81903197) and the National Natural Science Foundation of China (81630083).